Description
Release form
Infusion solution.
Packing
10 pcs.
Pharmacological action
Perlinganitis has a vasodilating, antianginal effect.
Indications
Angina pectoris (unstable and vasospastic), acute myocardial infarction, acute left ventricular failure, hypertensive crisis on the background of heart failure, controlled hypotension.
Contraindications
Acute circulatory failure (shock, vascular collapse) severe hypotension (systolic blood pressure below 95 mmHg) cardiogenic shock (while using drugs with positive inotropic effect or balloon counterpulsation).
Special instructions
Use infusion systems made of polyethylene, polypropylene, polytetrafluoroethylene or glass (but not polyvinyl chloride and polyurethane, since they adsorb the active substance and therefore may be required dose increase).
Composition of
1 ampoule with 10 ml of infusion solution contains 10 mg nitroglycerin in an isotonic 5% glucose solution.
Dosage and Administration
Perlinganite is administered iv through perfusion. Doses are selected individually, as a rule, 0.75-10.0 mg / h.
Side effects
Headache, drowsiness, weakness, decreased blood pressure, tachycardia, nausea, vomiting.
Drug interaction
When used simultaneously with other vasodilators (vasodilators), antihypertensive drugs, beta-blockers, calcium channel blockers, type 5 phosphodiesterase inhibitors, used to treat erectile dysfunction (for example, sildenafil), antipsychotics, tricyclic antidepressants, as well as ethanol, hypotensive effects may be enhanced.
With the simultaneous use of Perlinganite with dihydroergotamine, an increase in the concentration of dihydroergotamine in the blood may be noted, which leads to an increase in its hypotensive effect.
With the simultaneous use of heparin and perlinganitis, weakening of the effect of heparin is possible. Under the control of blood coagulation indicators, an appropriate dose of heparin is selected. After stopping the infusion of Perlinganitis, a significant decrease in blood coagulability is possible, which may require a reduction in the dose of heparin.
With the simultaneous use of a solution of Perlinganitis and tissue plasminogen activator, a decrease in blood concentration and a decrease in the effectiveness of the latter are described.
Overdose
Symptoms: a sharp decrease in blood pressure, reflex increase in heart rate, a feeling of general weakness, dizziness and lethargy, as well as headache, redness of the skin of the face or upper body, nausea, vomiting and diarrhea. When using the drug in high doses (more than 20 mg / kg body weight), methemoglobinemia, cyanosis, shortness of breath and tachypnea may increase intracranial pressure with cerebral symptoms.
Treatment: It is necessary to monitor the function of vital organs.
With severe arterial hypotension and / or shock, circulating blood volume should be increased. In exceptional cases, norepinephrine (norepinephrine) and / or dopamine can be infused. The use of epinephrine (adrenaline) and related substances is contraindicated.
The following antidotes are recommended for methemoglobinemia, depending on the severity: ascorbic acid (1 g orally or iv in the form of sodium salt) methylene blue (up to 50 mg of a 1% solution of methylene blue iv) toluidine blue (initial dose of 2-4 mg / kg iv weight if necessary repeat at hourly intervals of 2 mg / kg body weight). Oxygen therapy, hemodialysis, blood transfusion are indicated.
Storage conditions
At a temperature not exceeding 25 ° C.
Deystvuyuschee substances
Nytrohlytseryn
YUSB Pharma SA, Belgium
